이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Enfusion 관리

관리 기준 확인 3/4

Enfusion's CEO는 Oleg Movchan, Aug2022 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 1.46M, 44.7% 로 구성됩니다. 44.7% 급여 및 55.3% 보너스(회사 주식 및 옵션 포함). 는 $ 13.25M 가치에 해당하는 회사 주식의 1.27% 직접 소유합니다. 13.25M. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 3 년입니다.

주요 정보

Oleg Movchan

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	44.7%
CEO 임기	2.1yrs
CEO 소유권	1.3%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	3.2yrs

최근 관리 업데이트

Recent updates

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Dec 02

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Nov 08

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Oct 31

Enfusion Faces Cross-Currents In Investment Management Software Market

Aug 24

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11

Enfusion: Multiple Catalysts

Jun 20

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 08

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Dec 19

Enfusion Expands Offerings As Revenue Growth Decelerates

Oct 31

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 18

Enfusion gains after takeover report

Aug 31

Enfusion gets new interim CEO

Aug 22

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Aug 12

Enfusion: A Compelling Financial SaaS Company

Jun 24

CEO 보상 분석

Oleg Movchan 의 보수는 Enfusion 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$3m
Mar 31 2024	n/a	n/a	US$2m
Dec 31 2023	US$1m	US$650k	US$6m
Sep 30 2023	n/a	n/a	US$6m
Jun 30 2023	n/a	n/a	US$6m
Mar 31 2023	n/a	n/a	US$3m
Dec 31 2022	US$2m	US$236k	-US$9m

보상 대 시장: Oleg 의 총 보상 ($USD 1.46M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.43M ).

보상과 수익: Oleg 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Oleg Movchan (49 yo)

2.1yrs

테뉴어

US$1,455,190

보상

Mr. Oleg Movchan has been a Non-Executive Director at Enfusion, Inc since 2021 and a Member of the Board of Managers of Enfusion Ltd. LLC since February 2009. He served as an Interim Chief Executive Office...

리더십 팀

이름	위치	테뉴어	보상	소유권
Oleg Movchan	CEO & Director	2.1yrs	US$1.46m	1.25% $ 15.2m
Bradley Herring	Chief Financial Officer	1.8yrs	US$1.11m	0.018% $ 217.8k
Neal Pawar	Chief Operating Officer	less than a year	US$3.04m	0.038% $ 461.7k
Stephen Malherbe	Managing Partner	no data	데이터 없음	데이터 없음
Valeria Gutowski	Chief Accounting Officer	less than a year	데이터 없음	0.010% $ 123.2k
Daniel Groman	Chief Technology Officer	less than a year	데이터 없음	0.13% $ 1.6m
Ignatius Njoku	Head of Investor Relations	no data	데이터 없음	데이터 없음
Matthew Campobasso	General Counsel & Corporate Secretary	1.8yrs	데이터 없음	0.016% $ 196.4k
Bronwen Bastone	Chief People Officer	2.9yrs	US$1.86m	0.053% $ 648.6k
Joseph Defeo	Global Head of Managed Services Production	3.4yrs	데이터 없음	데이터 없음
Jeff Young	Head of Implementation	3.4yrs	데이터 없음	데이터 없음
Robert Taylor	Head of Client Support	3.4yrs	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: ENFN 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Oleg Movchan	CEO & Director	3.7yrs	US$1.46m	1.25% $ 15.2m
Bradford Bernstein	Independent Non-Executive Director	3.7yrs	데이터 없음	1.23% $ 14.9m
Lawrence Leibowitz	Independent Non-Executive Director	3.7yrs	US$228.17k	0.17% $ 2.1m
Deirdre Somers	Independent Director	1.7yrs	US$462.87k	0.020% $ 238.6k
Kathleen DeRose	Independent Non-Executive Director	2.8yrs	US$228.17k	0.045% $ 544.2k
Jan Hauser	Independent Non-Executive Director	2.8yrs	US$234.67k	0.044% $ 532.0k
Roy Luo	Independent Non-Executive Director	3.7yrs	데이터 없음	데이터 없음
Michael Spellacy	Independent Chairman	1.7yrs	US$658.20k	0.030% $ 364.4k

3.2yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: ENFN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Enfusion 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Recent updates

Enfusion Reportedly in Talks with Investment Bankers to Evaluate Options, Include Potential Sale

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Enfusion: Growth Should Accelerate In Coming Quarters

Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Consensus EPS estimates increase by 51%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Enfusion, Inc. Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility

New minor risk - Shareholder dilution

Enfusion, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

New minor risk - Shareholder dilution

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Consensus EPS estimates fall by 38%

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 20%, revenue upgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

New minor risk - Shareholder dilution

Now 20% undervalued after recent price drop

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 22% undervalued

New minor risk - Shareholder dilution

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Enfusion: Product Is Sticky And Industry Is Huge

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

CEO & Director recently sold US$1.0m worth of stock

New minor risk - Shareholder dilution

CEO & Director recently sold US$1.5m worth of stock

CEO & Director notifies of intention to sell stock

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Managing Partner recently sold US$9.9m worth of stock

Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 32%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Shareholder dilution

Enfusion Faces Cross-Currents In Investment Management Software Market

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Enfusion, Inc. Appoints Andi Woolass as Head of Partnerships and Alliances for EMEA

Enfusion Reportedly Draws Takeover Interest from Private Equity, Irenic Capital

Enfusion: Multiple Catalysts

Now 21% undervalued after recent price drop

Price target decreased by 7.1% to US$11.21

Chief Technology Officer recently sold US$396k worth of stock

Chief Technology Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Chief Technology Officer recently sold US$126k worth of stock

Chief Technology Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

Insider recently sold US$20m worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$2.26 loss in FY 2021)

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Enfusion, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Enfusion, Inc. Names Michael Spellacy as Board Chair and Non-Executive Director